Related Experiment Video

Updated: Jul 6, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

The management of pulmonary hypertension in children

S G Haworth1

  • 1Great Ormond Street Hospital for Children, London WC1N 3 JH, UK. s.haworth@ich.ucl.ac.uk

Archives of Disease in Childhood
|April 3, 2008
PubMed

Insights

Pediatric pulmonary hypertension management has evolved with new therapies. A specialized UK service offers expertise for severe cases, particularly idiopathic pulmonary arterial hypertension, using prostacyclin and exploring novel remodeling drugs.

Area of Science:

  • Pediatric cardiology and pulmonology
  • Vascular biology and pharmacology

Background:

  • Pediatric pulmonary hypertension (PPH) is a significant clinical challenge with diverse etiologies.
  • Recent advancements in pharmacotherapy have transformed PPH management over the last five years.
  • Diagnostic and therapeutic decision-making for PPH remains complex.

Purpose of the Study:

  • To describe the establishment and impact of the United Kingdom Pulmonary Hypertension Service for Children (UKPHSC).
  • To highlight current management strategies for severe pediatric pulmonary hypertension, including idiopathic pulmonary arterial hypertension (IPAH).
  • To discuss emerging therapeutic approaches targeting vascular remodeling.

Main Methods:

  • Establishment of a national specialized service (UKPHSC) in 2002.
  • Provision of expert advice, clinical expertise, and infrastructure support.
  • Focus on managing severely affected pediatric patients.

Main Results:

  • The UKPHSC has become a central resource for pediatric pulmonary hypertension management in the UK.
  • Chronic intravenous prostacyclin is identified as the most effective treatment for IPAH.
  • New pharmaceutical agents are being developed to structurally remodel pulmonary vasculature.

Conclusions:

  • Specialized national services are crucial for optimizing the care of children with pulmonary hypertension.
  • Prostacyclin therapy remains a cornerstone for severe IPAH in pediatric populations.
  • Future treatments aim for vascular normalization through structural remodeling, moving beyond vasodilation.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation